Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHORUS: Sotatercept in CpcPH and HFpEF
NCT07839585Phase 3Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2026
- Primary completion
- Jan 2030
01
Overview
A Phase 3 trial of sotatercept in pulmonary hypertension (PH), sponsored by Merck & Co.. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
sotatercept
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT07839585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07839585.